中国生物制药(01177.HK) 公布,与杭州先为达生物科技股份有限公司签署独家战略合作协议。据此,集团与先为达生物就其研发的人白细胞介素-29项目在中国、巴西、沙特阿拉伯、泰国、新加坡等19个国家达成独家许可与合作。(ca/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-27 16:25。)
AASTOCKS新闻Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.